Company intelligence / Profile preview

Shanghai Unicar-Therapy Bio-medicine Technology Co., Ltd.

Shanghai, Songjiang, Chinaunicar-therapy.com ↗

Ownership: Private
Development stage: Other

Overview

The company has multiple CAR-T therapies in development with their most advanced product (BCMA-CART) in Phase 3 for Multiple Myeloma. Their U-01 and other CD19-targeting CAR-T therapies have reached Phase 2 for various leukemias and lymphomas. Recent clinical trial results for their CAR-T therapies were presented at major conferences including ASH-2024, ESMO-2024, and EHA-2024.

Therapeutic areas: Oncology
Modalities: CAR-T cell therapiesChimeric antigen receptor T cell therapyGene therapiesImmunotherapiesMonoclonal antibodyNanobody
Industry: Biotech

Drug pipeline

20 assets

ssCART-19

19 more assets in the full pipeline.

Partnerships

Soochow UniversityThe Third Xiangya Hospital of Central South University

Beyond the preview

Go deeper on Shanghai Unicar-Therapy Bio-medicine Technology Co., Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shanghai Unicar-Therapy Bio-medicine Technology Co., Ltd..